

Exopharm Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Exopharm Limited
ABN:	78 163 765 991
Reporting period:	For the year ended 30 June 2023
Previous period:	For the year ended 30 June 2022

2. Results for announcement to the market

			\$
Revenues and other income from ordinary activities	down	19.0% to	3,411,087
Loss from ordinary activities after tax attributable to the owners of Exopharm Limited	down	29.3% to	(7,130,264)
Loss for the year attributable to the owners of Exopharm Limited	down	29.3% to	(7,130,264)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the Group after providing for income tax amounted to \$7,130,264 (30 June 2022: \$10,084,011).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>0.87</u>	<u>5.37</u>

4. Loss of control over entities

Not applicable.

5. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

6. Dividend reinvestment plans

Not applicable.

7. Details of associates and joint venture entities

Not applicable.

8. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

9. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unqualified opinion has been issued with an emphasis of matter for going concern.

10. Attachments

Details of attachments (if any):

The Annual Report of Exopharm Limited for the year ended 30 June 2023 is attached.

11. Signed



Signed _____

Date: 29 August 2023

Ian Dixon
CEO and Managing Director
Melbourne